News

BASF broadens enzyme business
Enlarge image

BusinessDenmarkGermany

BASF broadens enzyme business

16.05.2013 - German BASF AG has licensed Dyadic International's fungal enzyme manufacturing platform.

The German chemistry major will pay US$6m upfront to access Dyadic's C1 platform technology via a non-exclusive worldwide research and licence agreement. Under the term of the contract, BASF will fund research and development at Dyadic's research lab in the Netherlands and will use its thermophilic fungus Myceliopthora thermophila to develop, produce, distribute and sell industrial enzymes for a variety of applications. The US-headquartered company will cash in certain research and commercial milestone fees, as well as royalties upon commercialisation.  

"Dyadic's C1 technology will strengthen BASF's position in the industrial enzyme industry," said Dr. Carsten Sieden, Senior Vice President Fine Chemicals and Biocatalysis Research, BASF. "We expect this license agreement with Dyadic to result in promising long-term opportunities."

Dyadic's technology platform can be used for development and large scale manufacture of low cost proteins and enzymes as well as for screening of novel genes and proteins.  On the same day, BASF announced it has broadened its existing collaboration with Cologne-based Direvo Industrial Biotechnology GmbH, an expert in enzyme development and optimisation. The companies announced they will jointly develop a highly efficient protease for pig and poultry nutrition. Financial details were not disclosed.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/basf-broadens-enzyme-production.html

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%

FLOP

  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%

TOP

  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%

FLOP

  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%

TOP

  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%

FLOP

  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 03.05.2015